// App-Quantinova.ai

LB2364 : PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A PHASE 2 STUDY

Researchers

Presenter

  • Catherine Thieblemont

Principal Investigators

  • Tycel Phillips

  • Herve Ghesquieres

  • David Cunningham

  • Young Rok Do

  • Tatyana Feldman

  • Robin Gasiorowski

  • Wojciech Jurczak

  • Marjolein van der Poel

  • Michelle Limei Poon

  • Thomas Doerr

  • Nurgul Kilavuz

  • Mariana Sacchi

  • Brian Elliott

  • Martin Hutchings

  • Pieternella Lugtenburg

Medical Centers

  • Hackensack University Medical Center, Hackensack University Medical Center, Hackensack, NJ, United States.

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • National University Hospital, Singapore

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Sir Charles Gairdner Hospital, Perth, Australia

  • on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC,Utrecht,Niederlande

  • Vejle Hospital, Vejle, Denmark

  • Hôpitaux de Paris, Paris, France

  • Keimyung University Dongsan Medical Center, Daegu, Korea

  • University Hospitals Plymouth NHS Trust, Derriford Hospital,Plymouth,United Kingdom

  • Genmab,Princeton, NJ,United States

  • Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, Netherlands

  • National Reearch Instutute of Oncology, Poland

  • Assistance Publique &amp

  • Chonbuk National University Medical School, Jeonju, Korea, Republic of

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands

  • on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC,Utrecht,Niederlande

  • Hospices Civils de Lyon-Hopital Lyon Sud, Pierre-Benite, France

  • AbbVie, N Chicago, United States

  • APHP, Hôpital Saint-Louis, Hemato-Oncologie, Université de Paris,Paris,Frankreich

  • Concord Hospital, University of Sydney, Concord, Australia

Locations

  • France

  • United States

  • Australia

  • Denmark

  • United Kingdom

  • Republic of South Korea

  • Poland

  • Netherlands

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Cytokeratin 20

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03625037

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved